Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Stock Information for Protara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Protara Therapeutics Inc.

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.